Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC

Xue Li, Shimin Chen, Yuanyuan Shi, Yuanjing Wang, Xuanzhe Wang, Qian Lin, Chao Wu, Wenshuo Fang, Peng Sun, Leina Ma · 2024

Read Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC by Xue Li, Shimin Chen, Yuanyuan Shi, Yuanjing Wang, Xuanzhe Wang, Qian Lin, Chao Wu, Wenshuo Fang, Peng Sun, Leina Ma (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11688200.txt.

Description

A liver cancer drug often stops working as tumors learn to resist it. Xue Li and co-authors traced one resistance route in 2024, centered on a fat-handling protein called ACSL3. The drug kills cancer cells partly through ferroptosis, a death process driven by iron and fat damage, and the protein can block that process.

The team found the protein at abnormal levels in liver tumors, where it sped disease and dulled the drug. A gene switch named MEF2D binds the protein's control region and turns it up. Silencing the protein restored ferroptosis and drug sensitivity in their tests. The authors propose the switch and the protein as targets for making the drug work longer in liver cancer patients.

Catalog record

CREATORXue Li, Shimin Chen, Yuanyuan Shi, Yuanjing Wang, Xuanzhe Wang, Qian Lin, Chao Wu, Wenshuo Fang, Peng Sun, Leina Ma
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11688200

Browse the full library · About the Tower of Babel